Program
Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31
In AbbVie’s pipeline, CD19
. Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Dry Eye Syndromes, led by AbbVie.
Furthest: phase 1, since Aug 22, 20222 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 22 open or running | phase 1since Aug 22, 2022 | Aug 22, 2022 | Feb 2027phase 1 · NCT05512390 |
- Named in AbbVie’s own pipeline as
ABBV-319
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 22, 2022First study: phase 1 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT05512390 · 39 enrolled · United States, Australia, Canada and more
- May 12, 2025Phase 1 study in Dry Eye SyndromesNCT06977724 · 36 planned · United States, France, Netherlands
Ahead
- Feb 2027Primary completion: phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT05512390
- Mar 2029Primary completion: phase 1 study in Dry Eye SyndromesNCT06977724
TargetBeta
“CD19”the company's pipeline, read by Claude · source
“An antibody drug conjugate (ADC) composed of an afucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the B-cell-specific membrane protein CD19 ”NCIt, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06977724Dry Eye Syndromes · United States, France, Netherlands | 1 | Recruiting | Mar 2029 | 36 |
| NCT05512390Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada and more | 1 | Active, not recruiting | Feb 2027 | 39 |
How it is read
Names in the registry
- “ABBV-319”, 2 entries
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 1 study
- Dry Eye Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.